S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Prologis Stock Leading U.S. Logistics Boom
Abbott Laboratories Outlook is Healthy: Buy the Dip
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Prologis Stock Leading U.S. Logistics Boom
Abbott Laboratories Outlook is Healthy: Buy the Dip
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Prologis Stock Leading U.S. Logistics Boom
Abbott Laboratories Outlook is Healthy: Buy the Dip
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Prologis Stock Leading U.S. Logistics Boom
Abbott Laboratories Outlook is Healthy: Buy the Dip

Immuneering (IMRX) Earnings Date, Estimates & Call Transcripts

$1.86
+0.02 (+1.09%)
(As of 04/17/2024 ET)

Earnings Summary

Upcoming
Earnings Date
May. 2Estimated
Actual EPS
(Mar. 1)
-$0.52 Missed By -$0.06
Consensus EPS
(Mar. 1)
-$0.46
Skip Charts & View Estimated and Actual Earnings Data

IMRX Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

IMRX Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Immuneering Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20241($0.50)($0.50)($0.50)
Q2 20241($0.54)($0.54)($0.54)
Q3 20241($0.58)($0.58)($0.58)
Q4 20241($0.62)($0.62)($0.62)
FY 20244($2.24)($2.24)($2.24)

IMRX Earnings Date and Information

Immuneering last released its quarterly earnings data on March 1st, 2024. The reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.46) by $0.06. Immuneering has generated ($1.89) earnings per share over the last year (($1.89) diluted earnings per share). Earnings for Immuneering are expected to grow in the coming year, from ($1.89) to ($1.86) per share. Immuneering has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 2nd, 2024 based off prior year's report dates.

Immuneering Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/2/2024
Estimated)
------- 
3/1/2024Q4 2023($0.46)($0.52)($0.06)($0.52)--
11/9/2023Q3 2023($0.51)($0.43)+$0.08($0.43)--
8/3/2023Q2 2023($0.54)($0.43)+$0.11($0.43)--
5/4/2023Q1 2023($0.54)($0.51)+$0.03($0.51)--
3/6/2023Q4 2022($0.58)($0.50)+$0.08($0.50)--
11/10/2022Q3 2022($0.48)($0.49)($0.01)($0.49)$0.49 million$0.04 million
8/10/2022Q2 2022($0.52)($0.44)+$0.08($0.44)$0.27 million$0.09 million
5/10/2022Q1 2022($0.44)($0.49)($0.05)($0.49)$0.22 million$0.18 million
3/10/2022Q4 2021($0.39)($0.42)($0.03)($0.42)$0.60 million$0.19 million
11/8/2021Q3 2021($0.57)($0.47)+$0.10($0.47)$0.70 million$0.48 million
9/9/2021Q2 2021($1.66)($1.61)+$0.05($1.61)$0.70 million$0.66 million

Immuneering Earnings - Frequently Asked Questions

When is Immuneering's earnings date?

Immuneering has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 2nd, 2024 based off last year's report dates. Learn more on IMRX's earnings history.

Did Immuneering beat their earnings estimates last quarter?

In the previous quarter, Immuneering (NASDAQ:IMRX) missed the analysts' consensus estimate of ($0.46) by $0.06 with a reported earnings per share (EPS) of ($0.52). Learn more on analysts' earnings estimate vs. IMRX's actual earnings.

How much revenue does Immuneering generate each year?

Immuneering (NASDAQ:IMRX) has a recorded annual revenue of $320,000.00.

How much profit does Immuneering generate each year?

Immuneering (NASDAQ:IMRX) has a recorded net income of -$53.47 million. IMRX has generated -$1.89 earnings per share over the last four quarters.

What is Immuneering's EPS forecast for next year?

Immuneering's earnings are expected to grow from ($1.89) per share to ($1.86) per share in the next year.


More Earnings Resources from MarketBeat

This page (NASDAQ:IMRX) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners